Cann Group Ltd. (AU:CAN) has released an update.
Cann Group Limited, an Australian cannabis medicine company, has secured a $1 million advance from Endpoints Capital to support its business operations and ongoing research and development. This funding is an early access to the expected R&D Tax Incentive for the fiscal year 2024, which the company is set to receive. The advance, which carries an annual interest rate of 16%, will be repaid upon receipt of the R&D refund or by November 2024.
For further insights into AU:CAN stock, check out TipRanks’ Stock Analysis page.
